 |
|
Potential prostate cancer treatment improvements discovered by researchers at Cedars-Sinai
March 22, 2006Raloxifene, drug used for osteoporosis, shown to potentially benefit prostate cancer patients
In a study to be published in the April, 2006 issue of the British Journal of Urology International, researchers at Cedars-Sinai Medical Center have shown that Raloxifene, a drug commonly used to treat osteoporosis, has a potential clinical benefit in treating men with prostate cancer. This study has implications for the approximately 35,000 men who will die this year of advanced prostate cancer.
Prostate cancer is the leading cause of cancer and the second leading cause of cancer-related death among men living in the United States. Approximately one in six men will be diagnosed with prostate cancer during his lifetime. "We undertook this study because we desperately need new therapies for patients with advanced prostate cancer," said David B. Agus, M.D., research director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai and principal investigator of the study.
Since Raloxifene is a drug already on the market, researchers were able to move directly into a Phase II clinical trial. They identified the presence of the beta isoform of the estrogen receptor in prostate cancer tissue samples, then moved directly into studies of animals with human prostate cancer, and then onto human clinical trials. The entire process took only 2-3 years.
"It used to be that to show effectiveness through research studies, cancer drugs needed to shrink tumors by 50 percent," Agus said. "Now, the new way of thinking about the effectiveness of cancer drugs is whether they can slow cancer's growth, which ultimately may significantly benefit patients."
Through the study, patients were given a daily oral dosage of Raloxifene, and the disease and its symptoms were followed on a regular basis. Some of the patients in the clinical trial taking Raloxifene showed evidence of disease stabilization manifested by a slowing or stopping of the growth of their prostate cancer.
According to Ronald L. Shazer, M.D., primary author of the manuscript, "The outcome from the Phase II clinical trial merits further study in a randomized clinical trial to demonstrate the clinical benefit of this targeted therapy."
Cedars-Sinai Medical Center
Since Raloxifene is a drug already on the market, researchers were able to move directly into a Phase II clinical trial. They identified the presence of the beta isoform of the estrogen receptor in prostate cancer tissue samples, then moved directly into studies of animals with human prostate cancer, and then onto human clinical trials. The entire process took only 2-3 years.
"It used to be that to show effectiveness through research studies, cancer drugs needed to shrink tumors by 50 percent," Agus said. "Now, the new way of thinking about the effectiveness of cancer drugs is whether they can slow cancer's growth, which ultimately may significantly benefit patients."
Through the study, patients were given a daily oral dosage of Raloxifene, and the disease and its symptoms were followed on a regular basis. Some of the patients in the clinical trial taking Raloxifene showed evidence of disease stabilization manifested by a slowing or stopping of the growth of their prostate cancer.
According to Ronald L. Shazer, M.D., primary author of the manuscript, "The outcome from the Phase II clinical trial merits further study in a randomized clinical trial to demonstrate the clinical benefit of this targeted therapy."
Cedars-Sinai Medical Center
Prostate Cancer Treatment News and Current Prostate Cancer Treatment Events RSSMR imaging accurately determines prostate cancer treatment failure
Dynamic contrast-enhanced MRI (DCE-MRI) plus diffusion weighted imaging (DWI) can accurately diagnose residual or recurrent prostate cancer in patients treated with high-intensity focused ultrasonic ablation, a new study shows.
Prostate size and other neglected factors influence prostate cancer treatment satisfaction
Men with prostate cancer and their partners face difficult decisions regarding treatment, and accurate information regarding expected outcomes can be hard to find, according to results of a multi-center study published Wednesday in the New England Journal of Medicine.
'Mismatched' prostate cancer treatment more common than expected
More than a third of men with early prostate cancer who participated in a study analyzing treatment choice received therapies that might not be appropriate, based on pre-existing problems with urinary, bowel or sexual function.
Standard treatment for prostate cancer may encourage spread of disease
A popular prostate cancer treatment called androgen deprivation therapy may encourage prostate cancer cells to produce a protein that makes them more likely to spread throughout the body, a new study by Johns Hopkins researchers suggests.
New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
Michael Yarborough, a 58-year-old business owner from Waxahachie, Texas, was fortunate. A routine check-up three years ago revealed prostate cancer, but a side effect of his successful surgery was "driving him nuts."
Veterans exposed to Agent Orange have higher rates of prostate cancer recurrence
Veterans exposed to Agent Orange have a 48 percent increased risk of prostate cancer recurrence following surgery than their unexposed peers, and when the disease comes back, it seems more aggressive, researchers say.
Low education predicts lower quality of life for prostate cancer patients
Among men who have received similar treatments for prostate cancer, those with less education -- particularly those who did not graduate from high school -- experience a significant drop in their quality of life after treatment compared with men who have more education, according to a study led by researchers at the San Francisco VA Medical Center (SFVAMC).
PSA is poor predictor of lethal prostate cancer
The amount of prostate-specific antigen (PSA) in a man's bloodstream at the time of his prostate cancer diagnosis or its rate of change over the course of the disease does not adequately predict lethal prostate cancer.
IMRT versus 3D CRT for prostate cancer, new long-term data assesses side effects
New research findings show men have fewer long-term gastrointestinal side effects with intensity-modulated radiation therapy (IMRT) than with three-dimensional conformal radiation therapy (3D CRT) for prostate cancer treatment, despite the higher doses of radiation used in the IMRT group.
Prostate cancer research may be faster with PSA endpoints
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
More Prostate Cancer Treatment News Articles
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh, Janet Farrar Worthington EVERY MAN NEEDS THIS BOOK! Each year, more than 200,00 American men are diagnosed with prostate cancer. The good news is that more men are being cured of this disease than ever before. Now in a revised second edition, this lifesaving guide by Dr. Patrick Walsh and ard-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is... |
 | You Can Beat Prostate Cancer by Robert J. Marckini The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes... |
 | The Natural Prostate Cure by Roger Mason This book is the most completely researched book on natural prostate health. It gives you an effective alternative to the usual medical approach of surgery, radion and toxic drugs. Facts elaborate on include medical treatments for BPH often leave men in diapers unable to ever have sex again. Cure yourself of prostate problems safely, effectivelyl andnaturally based on clinical research. You... |
 | Surviving Prostate Cancer without Surgery: The New Gold Standard Treatment That Can Save Your Life and Lifestyle by Michael J., M.D. Dattoli, Jennifer Cash, Don Kaltenbach Unlike any other book on the subject, Surviving Prostate Cancer Without Surgery provides the most up-to-date information and lifesaving advice from three essential points of view -- physician, nurse, and patient-survivor. Three leading cancer care specialists guide readers step by step through diagnosis, treatment and recovery, covering both the physical and emotional challenges of the disease. ... |
 | Prostate And Cancer: A Family Guide To Diagnosis, Treatment And Survival (3rd Edition) by Sheldon Marks Prostate cancer has become the most-diagnosed cancer in America and the second leading killer of men. Sadly, more than 189,000 men will be diagnosed with the disease in 2002. Dr. Sheldon Marks, a specialist in the diagnosis and treatment of prostate cancer, is the authority that many have come to depend on-both in his practice and through his book, Prostate and Cancer-when cancer has posed a... |
 | The Prostate Cancer Treatment Book by Peter Grimm, John Blasko, John Sylvester The latest and most progressive treatment advice from prostate cancer experts at the nation's top medical centers For each of the nearly 200,000 Americans diagnosed with prostate cancer annually, the months following the diagnosis are a time of momentous decisions and enormous emotional strain. This book offers readers complete answers to all their questions about the best treatment options for... |
 | The Prostate Miracle: New Natural Therapies That Can Save Your Life by Dallas Clouatre, Jesse A. Stoff |
 | Beating Prostate Cancer (Hormonal Therapy & Diet, 1) by MD Charles "Snuffy" Myers Renowned prostate cancer oncologist and survivor, Dr Charles "Snuffy" Myers breaks down the ins and outs of prostate cancer treatment for patients everywhere. Details Include: Integrating A Comprehensive Approach To Treatment; Using Hormonal Therapy Alone Or With Radiation and Surgery To Prolong Life; Comprehensive Listing Of Vitamins, Diet, & Lifestyle Recommendations; Case Histories With High... |
 | How to Fight Prostate Cancer & Win by William L Fischer |
 | What Your Doctor May Not Tell You About(TM) Prostate Cancer: The Breakthrough Information and Treatments That Can Help Save Your Life (What Your Doctor May Not Tell You About...) by Glenn J. Bubley, Winifred Conkling DESCRIPTION: An expert in the field offers new and potentially life- saving alternative treatments for the #1 health concern of men over 50: prostate... |
| © 2008 BrightSurf.com |